Henry Schein (NASDAQ:HSIC) Stock Price Target Raised at UBS Group

Key Points

• UBS raised its price target on Henry Schein from $94 to $95 while maintaining a Neutral rating, implying 7.66% upside from the share price cited in the report.
• Analyst sentiment overall was more positive: MarketBeat reported a “Moderate Buy” consensus and an average price target of $93.33, with nine Buy, five Hold, and one Sell rating.
• Henry Schein reported quarterly EPS of $1.56, beating the $1.36 consensus, while revenue of $3.47 billion was slightly below expectations; revenue grew 4% year over year.

Henry Schein (NASDAQ:HSIC - Get Free Report) had its price objective raised by research analysts at UBS Group from $94.00 to $95.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. UBS Group's price objective would suggest a potential upside of 7.66% from the company's current price.

HSIC has been the topic of several other reports. Stifel Nicolaus set a $95.00 price objective on Henry Schein in a research note on Wednesday, August 5th. Weiss Ratings raised Henry Schein from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, August 21st. BTIG Research increased their target price on shares of Henry Schein from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, August 19th. Wall Street Zen raised shares of Henry Schein from a "hold" rating to a "buy" rating in a report on Monday, August 17th. Finally, BMO Capital Markets assumed coverage on shares of Henry Schein in a research note on Wednesday, July 8th. They issued a "market perform" rating and a $85.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Henry Schein Price Performance

HSIC traded up $5.74 during trading on Wednesday, hitting $88.24. 3,904,638 shares of the stock traded hands, compared to its average volume of 1,351,026. Henry Schein has a twelve month low of $68.70 and a twelve month high of $92.18. The company has a market cap of $9.83 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 1.56 and a beta of 0.87. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.32 and a quick ratio of 0.73. The business has a 50 day moving average price of $86.35 and a 200 day moving average price of $81.18.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.20. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%. The firm had revenue of $3.47 billion during the quarter, compared to analysts' expectations of $3.48 billion. During the same period in the prior year, the company earned $1.38 earnings per share. The company's quarterly revenue was up 4.0% on a year-over-year basis. Equities research analysts forecast that Henry Schein will post 5.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Southpoint Capital Advisors LP grew its position in shares of Henry Schein by 28.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company's stock valued at $235,840,000 after buying an additional 700,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Henry Schein in the second quarter valued at about $42,261,000. Staley Capital Advisers Inc. raised its position in shares of Henry Schein by 12,115.2% during the first quarter. Staley Capital Advisers Inc. now owns 450,740 shares of the company's stock worth $33,220,000 after acquiring an additional 447,050 shares during the last quarter. Defilade Capital Management L.P. raised its position in shares of Henry Schein by 94.8% during the first quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company's stock worth $45,992,000 after acquiring an additional 303,615 shares during the last quarter. Finally, Bank of Nova Scotia raised its position in shares of Henry Schein by 1,263.1% during the first quarter. Bank of Nova Scotia now owns 116,808 shares of the company's stock worth $8,609,000 after acquiring an additional 108,239 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company's stock.

Trending Headlines about Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Henry Schein reported Q3 EPS of $1.56, above the roughly $1.34–$1.36 analyst estimates cited in reports and up from $1.38 a year earlier. The company also raised its FY2026 EPS guidance, supporting the earnings outlook. Henry Schein Q3 results and guidance
• Positive Sentiment: Sales grew 4.0% year over year to about $3.47 billion, with recent analysis pointing to volume-driven dental gains and margin initiatives as operating supports. Q3 business and margin analysis
• Neutral Sentiment: Revenue was nearly in line with expectations, rather than a clear top-line beat. A tariff refund also contributed to the quarter, so investors may assess how much of the performance can be sustained through ongoing operations. Q3 revenue results
• Negative Sentiment: Delays in discretionary dental procedures are weighing on demand and tempering the otherwise strong earnings report, a risk that may limit confidence in near-term growth. Discretionary dental delays

About Henry Schein

Henry Schein, Inc NASDAQ: HSIC is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.